NASDAQ:SNOA

Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis

Sonoma Pharmaceuticals logo
$0.72 -0.09 (-10.83%)
Closing price 04:00 PM Eastern
Extended Trading
$0.72 -0.01 (-0.69%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA)

Advanced

Key Stats

Today's Range
$0.72
▼
$0.84
50-Day Range
$0.81
▼
$1.30
52-Week Range
$0.72
▼
$3.95
Volume
103,745 shs
Average Volume
82,674 shs
Market Capitalization
$3.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Sell

Company Overview

Sonoma Pharmaceuticals develops and markets products based on its stabilized hypochlorous acid technology for human and animal health. Its product portfolio includes solutions and gels for wound care, skin conditions, eye care and other hygiene applications.

The company’s offerings include Microcyn-branded products, which are used in areas such as wound management and dermatology, as well as products for veterinary care. Sonoma sells its products through commercial partners and distributors in the United States and international markets.

The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016. Its business has since focused on developing and commercializing hypochlorous acid-based products for healthcare and related markets.

AI Generated. May Contain Errors.

Sonoma Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
12th Percentile Overall Score

SNOA MarketRank™: 
0.58173076923 of 5 stars

Sonoma Pharmaceuticals scored higher than 12% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Sonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Sonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Sonoma Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Sonoma Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Sonoma Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Sonoma Pharmaceuticals has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.41% of the float of Sonoma Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Sonoma Pharmaceuticals has a short interest ratio ("days to cover") of 1.67, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Sonoma Pharmaceuticals has recently decreased by 38.73%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Sonoma Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Sonoma Pharmaceuticals does not have a long track record of dividend growth.

  • MarketBeat Follows

    3 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    1.02% of the stock of Sonoma Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.

  • Read more about Sonoma Pharmaceuticals' insider trading history.
Receive SNOA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNOA Stock News Headlines

URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.tc pixel
See More Headlines

SNOA Stock Analysis - Frequently Asked Questions

Sonoma Pharmaceuticals' stock was trading at $3.64 at the beginning of the year. Since then, SNOA stock has decreased by 80.2% and is now trading at $0.7220.

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its earnings results on Tuesday, November, 10th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of ($0.10) by $0.19. The business had revenue of $7.17 million for the quarter, compared to analyst estimates of $5.29 million. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 4.82% and a negative net margin of 7.65%.

Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), American Airlines Group (AAL), BigBear.ai (BBAI) and GE Aerospace (GE).

Company Calendar

Last Earnings
11/10/2026
Today
11/20/2026
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:SNOA
CIK
1367083
Employees
260
Year Founded
1999

Profitability

EPS (Trailing Twelve Months)
($0.91)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$3.17 million
Net Margins
-7.65%
Pretax Margin
-5.93%
Return on Equity
-4.82%
Return on Assets
-1.52%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.48
Quick Ratio
2.68

Sales & Book Value

Annual Sales
$19.53 million
Price / Sales
0.19
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.31 per share
Price / Book
0.55

Miscellaneous

Outstanding Shares
5,060,000
Free Float
5,010,000
Market Cap
$3.65 million
Optionable
Not Optionable
Beta
1.31

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:SNOA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners